You are here

  • Home
  • Archive
  • Volume 79, Issue 2
  • Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids

Article Text

Article menu
Download PDFPDF
Correspondence
Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
  1. Julia Herrou,
  2. Victoire De Lastours
  1. Department of Medicine, Beaujon University Hospital, Clichy, France
  1. Correspondence to Mrs Julia Herrou, Department of Medicine, Beaujon University Hospital, Clichy 92110, France; juliaherrou92{at}hotmail.fr

http://dx.doi.org/10.1136/annrheumdis-2018-214718

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the article by Jun Won Park et al, describing in a retrospective study the prophylactic effect of trimethoprim-sulfamethoxazole (TMP-SMX) to prevent Pneumocystis jiroveci pneumonia (PCP) in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.1 High-dose glucocorticoid is indeed a well-known and major risk factor for PCP supporting the investigation carried out here. The conclusions of the work are that TMP-SMX prophylaxis is very effective and safe at preventing PCP.2 …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.